apatinib and Carcinoma--Lewis-Lung

Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Lewis Lung; Cell Line, Tumor; Humans; Lung Neoplasms; Lymphocytes, Tumor-Infiltrating; Male; Mice, Inbred C57BL; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyridines; Tumor Microenvironment

Abnormal vascular network of tumor can create a hypoxic microenvironment, and reduce radiotherapy sensitivity. Normalization of tumor vasculature can be a new therapeutic strategy for sensitizing radiotherapy. This study aimed to explore the effect of apatinib on vascular normalization, as well as the syngeneic effect with radiotherapy on lung cancer.. Lewis lung carcinoma (LLC) xenograft-bearing female C57BL/6 mice were treated with different doses of apatinib (30, 60, and 120 mg/kg per day) and/or radiation therapy (8 Gy/1F) and then sacrificed to harvest tumor tissue for immunohistochemical test. Further. Our data suggested that low- dose apatinib can successfully induce a vascular normalization window and function as a radio- sensitizer in the lung cancer xenografts model.

Topics: Animals; Carcinoma, Lewis Lung; Cell Line, Tumor; Female; Humans; Hypoxia; Lung Neoplasms; Mice; Mice, Inbred C57BL; Radiation-Sensitizing Agents; Tumor Microenvironment

Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Proliferation; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Pyridines